Surfactant-based drug delivery systems for treating drug-resistant lung cancer

Drug Delivery

Volumn 23, Issue 3, 2016, Pages 727-738

  Kaur, Prabhjot ^a   Garg, Tarun ^a   Rath, Goutam ^a   Murthy, R S R ^a   Goyal, Amit K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Drug resistance; Glycoprotein; Lung cancer; Nanotechnological carriers; Surfactants

Indexed keywords

ANTINEOPLASTIC AGENT; SURFACTANT;

ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; LUNG NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; SURFACE-ACTIVE AGENTS;

EID: 84958166982     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.935530     Document Type: Review

References (116)

1. Anand P, Sundaram C, Jhurani S, et al. (2008). Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 267: 133-64
2. Bailey MM, Berkland CJ. (2009). Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 29: 196-212
3. Bansal T, Jaggi M, Khar R, Talegaonkar S. (2009). Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12: 46-78
4. Batrakova EV, Han H-Y, Alakhov VY, et al. (1998). Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm Res 15: 850-5
5. Batrakova EV, Kabanov AV. (2008). Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Rel 130: 98-106
6. Bergers G, Benjamin LE. (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-10
7. Bonomi P, Kim K, Fairclough D, et al. (2000). Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-31
8. Brabender J, Danenberg KD, Metzger R, et al. (2001). Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7: 1850-5
9. Bunn P, Kelly, K. (1998). New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4: 1087-100
10. Chavanpatil MD, Patil Y, Panyam J. (2006). Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm 320: 150-6
11. Chen Y-T, Feng B, Chen L-B. (2012). Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pac J Cancer Prev 13: 3577-81
12. Chougule MB, Padhi BK, Misra, A. (2006). Nano-liposomal dry powder inhaler of amiloride hydrochloride. J Nanosci Nanotechnol 6: 9-10
13. Collnot E-M, Baldes C, Wempe MF, et al. (2007). Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm 4: 465-74
14. Cornaire G, Woodley J, Hermann P, et al. (2004). Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharma 278: 119-31
15. Dabholkar RD, Sawant RM, Mongayt DA, et al. (2006). Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loaDing with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm 315: 148-57
16. Davis W, Pfeiffer R, Quay J. (1970). Normal and promoted gastrointestinal absorption of water-soluble substances I: induced rapidly reversible hyperabsorptive state in the canine fundic stomach pouch. J Pharm Sci 59: 960-3
17. de Vore R, Johnson David, H. (2000). Chemotherapy for small cell lung cancer. lung cancer: principles and practice. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins
18. Dickinson, E. (1992). Introduction to food colloids. Oxford, UK: Oxford University Press
19. Du J, Lu W-L, Ying X, et al. (2009). Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm 6: 905-17
20. Eberhardt W, Korfee, S. (2003). New approaches for small-cell lung cancer: local treatments. Cancer Control 10: 289-96
21. Elkharraz K, Faisant N, Guse C, et al. (2006). Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization. Int J Pharm 314: 127-36
22. Emilienne Soma C, Dubernet C, Bentolila D, et al. (2000). Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21: 1-7
23. Ettinger DS. (2002). Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer? Oncologist 7: 226-33
24. Ferrara, N. (2002). Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 10:10-14
25. Ferrara N, Gerber H-P, Lecouter, J. (2003). The biology of VEGF and its receptors. Nat Med 9: 669-76
26. Ferrara N, Hillan KJ, Gerber H-P, Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400
27. Föger F, Schmitz T, Bernkop-Schnürch, A. (2006). In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials 27: 4250-5
28. Folkman J, Merler E, Abernathy C, Williams, G. (1971). Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133: 275-88
29. Fong KM, Sekido Y, Minna JD. (1999). Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 118: 1136-52
30. Fossella FV, Devore R, Kerr RN, et al. (2000). Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18: 2354-62
31. Gagandeep G, Garg T, Malik B, et al. (2014). Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci 53: 10-16
32. García Sar D, Aguado L, Montes Bayón M, et al. (2012). Relationships between cisplatin-induced adducts and DNA strand-breaks, mutation and recombination in vivo in somatic cells of Drosophila melanogaster, under different conditions of nucleotide excision repair. Mutat Res Genet Toxicol Environ Mutagen 741: 81-8
33. Garg, T. (2014). Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne. Artif Cells Nanomed Biotechnol 20: 1-8
34. Garg T, Goyal AK. (2012). Iontophoresis: drug delivery system by applying an electrical potential across the skin. Drug Deliv Lett 2: 270-80
35. Garg T, Goyal AK. (2014a). Biomaterial-based scaffolds-current status and future directions. Expert Opin Drug Deliv 11: 767-89
36. Garg T, Goyal AK. (2014b). Liposomes: targeted and controlled delivery system. Drug Deliv Lett 4: 62-71
37. Garg T, Rath G, Goyal AK. (2014). Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv. [Epub ahead of print]
38. Garg T, Singh O, Arora S, Murthy, R. (2012). Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst 29: 1-63
39. Garg T, Singh S, Goyal AK. (2013). Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst 30: 369-409
40. Giantonio BJ, Catalano PJ, Meropol NJ, et al. (2007). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-44
41. Goyal AK, Rath G, Garg T. (2013a). Nanotechnological Approaches for Genetic Immunization. DNA RNA Nanobiotechnol Med Diagn Treat Dis 67-120
42. Goyal G, Garg T, Malik B, et al. (2013b). Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv
43. Greco FA, Gray JR, Thompson DS, et al. (2002). Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma. Cancer 95: 1279-85
44. Griffin WC. (1955). Calculation of HLB values of non-ionic surfactants. Am Perfumer Essent Oil Rev 65: 26-9
45. Group, N-SCLCC. (1995). Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909
46. Guillemard V, Saragovi HU. (2004). Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene 23: 3613-21
47. Hainsworth JD, Sosman JA, Spigel DR, et al. (2005). Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23: 7889-96
48. Hande, K. (1998). Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34: 1514-21
49. Haura EB. (2001). Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 8: 326-36
50. Hitzman CJ, Elmquist WF, Wattenberg LW, Wiedmann TS. (2006). Development of a respirable, sustained release microcarrier for 5-fluorouracil I: in vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci 95: 1114-26
51. Ho EA, Soo PL, Allen C, Piquette-Miller, M. (2007). Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J Control Rel 117: 20-7
52. Holmberg, K. (2003). Novel surfactants: preparation applications and biodegradability, revised and expanded. Florida, USA: CRC Press
53. Hosomi Y, Shibuya M, Niho S, et al. (2011). Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. Anticancer Res 31: 3449-56
54. Hunter TB, Manimala NJ, Luddy KA, et al. (2011). Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. Anticancer Res 31: 3193-204
55. Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350: 2335-42
56. Iffert T, Soldan M, Moeller A, Maser, E. (2000). Modulation of daunorubicin toxicity by liposomal encapsulation and use of specific inhibitors in vitro. Toxicology 144: 189-95
57. Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. Cancer J Clin 61: 69-90
58. Kataria K, Sharma A, Garg T, et al. (2014). Novel technology to improve drug loaDing in polymeric nanofibers. Drug Deliv Lett 4: 79-86
59. Kaur M, Garg T, Rath G, Goyal AK. (2014a). Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst 31: 49-88
60. Kaur M, Malik B, Garg T, et al. (2014b). Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv
61. Kaur R, Garg T, Malik B, et al. (2014c). Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs. Drug Deliv 1-6. [Epub ahead of print]
62. Kelsey CR, Clough RW, Marks LB. (2006). Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. Cancer J 12: 283-8
63. Koziara JM, Whisman TR, Tseng MT, Mumper RJ. (2006). In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Rel 112: 312-19
64. Lamprecht A, Benoit J-P. (2006). Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Rel 112: 208-13
65. Leighl, N. (2012). Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol 19:S52-8
66. Lin J-K. (2007). Molecular targets of curcumin. The molecular targets and therapeutic uses of curcumin in health and disease. New York, USA: Springer
67. Lo Y-L. (2003). Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Control Rel 90: 37-48
68. Massarelli E, Andre F, Liu D, et al. (2003). A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens incluDing platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39: 55-61
69. Mehnert W, Mäder, K. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47: 165-96
70. Miller K, Wang M, Gralow J, et al. (2005). A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Research and Treatment. New York, NY: Springer 233 Spring Street, S6-6
71. Minchinton AI, Tannock IF. (2006). Drug penetration in solid tumours. Nat Rev Cancer 6: 583-92
72. Novello S, Longo M, Levra MG. (2007). Toward therapies tailored to patient characteristics. J Thorac Oncol 2: S38-41
73. Nurwidya F, Takahashi F, Murakami A, Takahashi, K. (2012). Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 44: 151-6
74. Ohe Y, Ohashi Y, Kubota K, et al. (2007). Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Annals Oncol 18: 317-23
75. Parnami N, Garg T, Rath G, Goyal AK. (2013). Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol
76. Patel NR, Rathi A, Mongayt D, Torchilin VP. (2011). Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm 416: 296-9
77. Patil Y, Sadhukha T, Ma L, Panyam, J. (2009). Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Rel 136: 21-9
78. Patton JS, Byron PR. (2007). Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6: 67-74
79. Pfister DG, Johnson DH, Azzoli CG, et al. (2004). American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-53
80. Pore MM, Hiltermann TJN, Kruyt FA. (2013). Targeting apoptosis pathways in lung cancer. Cancer Lett 332: 359-68
81. Rege BD, Kao JP, Polli JE. (2002). Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 16: 237-46
82. Riehm H, Biedler JL. (1972). Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin. Cancer Res 32: 1195-200
83. Roberti A, Sala DL, Cinti, C. (2006). Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol 207: 571-81
84. Rodriguez E, Lilenbaum RC. (2010). Small cell lung cancer: past, present, and future. Curr Oncol Rep 12: 327-34
85. Rusch V, Klimstra D, Venkatraman E, et al. (1997). Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3: 515-22
86. Saintigny P, Burger JA. (2012). Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 13: 287-97
87. Sandler A, Gray R, Perry MC, et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-50
88. Scagliotti G, de Marinis F, RinalDi M, et al. (2002). Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20: 4285-91
89. Schiller JH, Harrington D, Belani CP, et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-8
90. Shepherd FA, Crowley J, van Houtte P, et al. (2007). The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarDing the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2: 1067-77
91. Shepherd FA, Dancey J, Ramlau R, et al. (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-103
92. Siegel R, Naishadham D, Jemal, A. (2012). Cancer statistics, 2012. Cancer J Clin 62: 10-29
93. Singh H, Sharma R, Joshi M, et al. (2014a). Transmucosal delivery of docetaxel by mucoadhesive polymeric nanofibers. Artif Cells Nanomed Biotechnol
94. Singh O, Garg T, Rath G, Goyal AK. (2014b). Microbicides for the treatment of sexually transmitted hiv infections. J Pharm 1-18
95. Smit E, Carney D, Harford P, et al. (1989). A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44: 631-3
96. Smit EF, van Meerbeeck JP, Lianes P, et al. (2003). Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21: 3909-17
97. Solans C, Kunieda, H. (1996). Industrial applications of microemulsions. New York, USA: Marcel Dekker
98. Song XR, Cai Z, Zheng Y, et al. (2009). Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 37: 300-5
99. Štastný M, Plocová D, Etrych T, et al. (2002). HPMA-hydrogels containing cytostatic drugs: kinetics of the drug release and in vivo efficacy. J Control Rel 81: 101-11
100. Štastný M, Strohalm J, Plocova D, et al. (1999). A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer carrier. Eur J Cancer 35: 459-66
101. Subramanian J, Waqar SN, Govindan, R. (2011). Targeted therapy in lung cancer: lessons learned from past experiences. J Thorac Oncol 6: S1786-8
102. Sung JC, Pulliam BL, Edwards DA. (2007). Nanoparticles for drug delivery to the lungs. Trends Biotechnol 25: 563-70
103. Suttipong M, Tummala NR, Kitiyanan B, Striolo, A. (2011). Role of surfactant molecular structure on self-assembly: aqueous SDBS on carbon nanotubes. J Phys Chem C 115: 17286-96
104. Tummala NR, Striolo, A. (2009). SDS surfactants on carbon nanotubes: aggregate morphology. ACS Nano 3: 595-602
105. Vinogradov SV, Zeman AD, Batrakova EV, Kabanov AV. (2005). Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J Control Rel 107: 143-57
106. Vogelsang GB, Abeloff MD, Ettinger DS, Booker SV. (1985). Long-term survivors of small cell carcinoma of the lung. Am J Med 79: 49-56
107. Wong HL, Bendayan R, Rauth AM, Wu XY. (2006). Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Rel 116: 275-84
108. Woodcock D, Linsenmeyer M, Chojnowski G, et al. (1992). Reversal of multidrug resistance by surfactants. Br J Cancer 66: 62-8
109. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. (1998). Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16: 2459-65
110. Wu J, Lu Y, Lee A, et al. (2007). Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 10: 350-7
111. Wu S-H, Hang L-W, Yang J-S, et al. (2010). Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade-and mitochondria-dependent pathways. Anticancer Res 30: 2125-33
112. Xiao Yan L, McTan T, Lee H. (2005). In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull 28: 822-8
113. Yang S, Gursoy RN, Lambert G, Benita, S. (2004). Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 21: 261-70
114. Yang W, Peters JI, Williams RO III. (2008). Inhaled nanoparticles-A current review. Int J Pharm 356: 239-47
115. Zhang Z, Feng S-S. (2006a). The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly (lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27: 4025-33
116. Zhang Z, Feng S-S. (2006b). Self-assembled nanoparticles of poly (lactide)-vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm 324: 191-8